| 证券代码：603939 | 证券简称：益丰药房 公告编号：2025-072 | | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | 益丰大药房连锁股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 公司控股股东宁波梅山保税港区厚信创业投资合伙企业（有限合伙）及其一致行动 人宁波梅山保税港区益之丰企业管理合伙企业（有限合伙）、宁波梅山保税港区益仁堂 企业管理合伙企业（有限合伙）、高毅先生保证向本公司提供的信息真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少 | | --- | --- | --- | --- | | 权益变动前合计比例 | 34.85% | | | | 权益变动后合计比例 | 32.85% | | | | 本次变动是否违反已作出的承 | 是□ | 否 | | | 诺、意向、计划 | | | | | 是否触发强制要约收购义务 | 是□ | 否 | | 3.一致行动人信息 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | 控股股东/实际控制人 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 减持计划实施前股东持股的基本情况 本次减持计划实施前，益丰大药房连锁股份有限公司（以下简称"公司"）控 股股东宁波梅山保税港区厚信创业投资合伙企业（有限合伙）（以下简称"厚信创 投"）持有公司无限售流通股 262,492,776 股，占公司总股本 21.65%。 公司控股股东厚信创投的一致行动人宁波梅山保税港区益之丰企业管理合 伙企业（有限合伙）（以下简称"益之丰"）持有公司无限售流通股 12,692,782 股， 占公司总股本 1.05%。 公司控股股东厚信创投的一致行动人宁波梅山保税港区益仁堂企业管理合 伙企业（有限合伙）（以下简称"益仁堂"）持有公司无限售流通股 5,816,466 股， 占公司总股本 0.48 ...

益丰药房公告，控股股东宁波梅山保税港区厚信创业投资合伙企业（有限合伙）及一致行动人宁波梅山 保税港区益之丰企业管理合伙企业（有限合伙）、宁波梅山保税港区益仁堂企业管理合伙企业（有限合 伙）已于2025年8月5日至2025年8月6日通过大宗交易累计减持2424.82万股，占公司总股本2.00%；其中 厚信创投减持2147.19万股，占1.77%，益之丰减持190.39万股，占0.16%，益仁堂减持87.24万股，占 0.07%，减持计划已实施完毕。 ...

| 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 259.87 | 5945.83 | 22.88 | -6.42 | 摩根大通证券（中国）有限公司 | 中信证券股份有限 | | | | | | 上海银城中路证券营业部 | 公司湖南分公司 | | 190.39 | 4356.12 | 22.88 | -6.42 | 国泰海通证券股份有限公司总部 | 中信证券股份有限 | | | | | | | 公司湖南分公司 | | 184.10 | 4212.21 | 22.88 | -6.42 | 国泰海通证券股份有限公司总部 | 中信证券股份有限 | | | | | | | 公司湖南分公司 | | 150.00 | 3432.00 | 22.88 | -6.42 | 机构专用 | 中信证券股份有限 | | | | | | | 公司湖南分公司 | | 100.00 | 2288.00 | 22.88 ...

8月5日，益丰药房大宗交易成交2352.65万股，成交额5.38亿元，占当日总成交额的85.48%，成交价 22.88元，较市场收盘价24.45元折价6.42%。 | 交易日期 | 证券同核 | 证券代品 | | | 痰交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 群用易不错 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-05 | 草本配送 | 603939 | 22.88 | 204.55 | 8.94 | 机构专用 | 中信证券股份有限 公司减附分公司 | 零 | | 2025-08-05 | 草丰厨房 | 603839 | 22.88 | 203.63 | 8.9 | 机构专用 | 中信证券股份有限 公司湖南分公司 | Ka | | 2025-08-05 | 草本配送 | 603939 | 22.88 | 202.95 | 8.87 | 机构专用 | 中信证券股份有限 公司湖南分公司 | 整 | | 2025-08-05 | 群主经论 | 603939 | 22.88 | 202. ...

Core Viewpoint - The first "Excellent Cases of ESG Practices by Enterprises in the Yangtze River Economic Belt" conference highlighted the importance of ESG (Environmental, Social, and Governance) as a key evaluation system for sustainable development, emphasizing its role in reshaping corporate value and driving industrial transformation [3][4]. Group 1: ESG Policy and Development - Recent years have seen a surge in ESG policies in China, with the Shanghai and Shenzhen Stock Exchanges set to enforce mandatory disclosure of sustainability reports starting April 2024, prioritizing climate change responses [3]. - The Ministry of Finance has integrated climate-related content into its guidelines, aligning with the national "dual carbon" goals [3]. - The State-owned Assets Supervision and Administration Commission has issued guidelines for central enterprises to fulfill social responsibilities, with local state-owned asset management offices also releasing related opinions [3]. Group 2: Corporate Participation and Innovation - Enterprises along the Yangtze River Economic Belt are accelerating their transformation towards a green economy, becoming a key battleground for ecological priority and green development in China [3]. - A diverse group of nearly 100 representatives from central and local state-owned enterprises, as well as large private companies, gathered to discuss innovative approaches to sustainable development and the integration of ESG principles [4]. - The conference featured 45 companies recognized for their outstanding ESG practices in 2024, showcasing their innovative measures through video presentations [5].

证券之星消息，8月4日医药商业板块较上一交易日下跌0.23%，塞力医疗领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 目洋医药 | 22.39 | 1.91% | 12.41万 | 2.71亿 | | 603939 | 益丰药房 | 24.60 | 1.61% | 6.75万 | 1.65亿 | | 603233 | 大参林 | 17.58 | 0.92% | 4.67万 | 8141.04万 | | 600511 | 国药股份 | 30.04 | 0.74% | 5.65万 | 1.69亿 | | 603122 | 合富中国 | 7.28 | 0.55% | 6.14万 | 4434.06万 | | 301017 | 漱玉平民 | 13.35 | 0.45% | 6.99万 | 9203.55万 | | 605266 | 健之佳 | 22.0 ...

Core Insights - The Chinese pharmaceutical distribution market is segmented into three competitive tiers, with major players like China National Pharmaceutical, Shanghai Pharmaceuticals, and China Resources Pharmaceutical leading the first tier with revenues exceeding 100 billion [1] - The retail pharmacy rankings show Dazhenlin at the top, followed by Guoda Pharmacy and Yifeng Pharmacy, indicating significant changes in the rankings from 2022-2023 [3][4] - In the e-commerce sector, Fangzhou Jianke leads the online pharmacy rankings, emphasizing the shift towards technology-driven healthcare solutions [5] Competitive Landscape - The pharmaceutical distribution industry is characterized by intense competition, with numerous participants including wholesale, retail, and brand operation companies, as well as e-commerce platforms entering the market [7] - The five forces analysis indicates a high threat from potential entrants and moderate bargaining power from downstream medical institutions and patients [7] - The strategic cluster analysis reveals that leading companies like China Resources Pharmaceutical and Shanghai Pharmaceuticals are positioned as market leaders due to their extensive experience and comprehensive business layouts [5][6] Retail Pharmacy Rankings - The top five retail pharmacies are Dazhenlin, Guoda Pharmacy, Yifeng Pharmacy, Laobaiyi, and Yixintang, reflecting a dynamic market with significant shifts in rankings [3][4] - Other notable pharmacies in the top 25 include Henan Zhang Zhongjing Pharmacy and Shandong Yanjitang, showcasing a diverse competitive landscape [3] E-commerce Pharmacy Rankings - Fangzhou Jianke leads the online pharmacy sector, followed by 1Yao.com and JD Health, highlighting the growing importance of digital platforms in the pharmaceutical distribution market [5] - The focus on technology and innovation is evident as companies aim to connect patients with medical services more effectively [5]

Core Viewpoint - The regulatory authority has imposed penalties on Jiaying Pharmaceutical and its responsible individuals for violations related to information disclosure, specifically concerning the failure to timely disclose a 220 million yuan related party fund borrowing [1][2]. Summary by Sections Regulatory Actions - Jiaying Pharmaceutical and its key personnel received a total fine of 4.9 million yuan due to the failure to disclose 220 million yuan in related party fund borrowing [1][2]. - The Guangdong Securities Regulatory Bureau issued a warning and fines of 1.5 million yuan to Jiaying Pharmaceutical, 1.6 million yuan to Chairman Li Neng, 1 million yuan to General Manager You Yongping, and 800,000 yuan to former CFO Shi Junping [3]. Related Party Transactions - The related party transactions involved Jiaying Pharmaceutical's subsidiary, Jiaying Pharmaceutical (Hunan) Co., Ltd., providing short-term fund borrowing to Hunan Yaoyang, a company controlled by Li Neng, with amounts ranging from 40,000 to 59.99 million yuan [2][3]. - The total amount borrowed in 2024 was 170 million yuan, with an additional 50 million yuan in January 2025, representing 28.83% of Jiaying Pharmaceutical's latest audited net assets [2]. Management Accountability - Li Neng, as the chairman, is directly responsible for the information disclosure violations, while You Yongping and Shi Junping also hold direct responsibility due to their managerial roles [3]. - The violations occurred shortly after Li Neng's appointment as chairman, indicating potential misconduct in managing company funds [4]. Financial Context of Related Companies - Hunan Yaoyang, controlled by Li Neng, has faced significant financial challenges, with 2024 revenues of 1.165 billion yuan and a net profit of 49.93 million yuan, which are substantially lower compared to competitors [5]. - The company has struggled to secure financing through public offerings, leading to reliance on brand cooperation and franchise models, resulting in only about 4,000 stores compared to competitors with over 10,000 [5].

因信息披露违法违规被立案后，监管对嘉应制药（002198）及相关责任人的处罚落地。此前公司在5月 28日晚曾公告，因公司涉嫌信息披露违法违规，中国证监会决定对公司立案。（详见本报5月29日报道 本报报道后，002198被立案调查了！） 8月3日晚间，嘉应制药公告，8月1日，公司及相关责任人李能（现任董事长）、游永平（现任董事、总 经理）、史俊平（时任财务总监）收到中国证监会广东监管局下发的《行政处罚事先告知书》（以下简 称《行政处罚书》），因2.2亿元关联资金拆借未及时披露，嘉应制药及相关责任人合计领490万元罚 单。 嘉应制药及相关责任人领490万元罚单 《行政处罚书》显示，嘉应制药董事长李能是湖南药聚能医药有限公司（以下简称"药聚能"）的实际控 制人，药聚能构成嘉应制药的关联方。2024年10月至2025年1月期间，因药聚能存在短期资金需求，嘉 应制药的子公司嘉应制药（湖南）有限公司（以下简称"湖南嘉应"）以月初转出、月末转回的方式，向 药聚能提供短期资金拆借，单笔发生额在4万元至5999万元之间。其中，2024年度合计转出1.7亿元； 2025年1月转出5000万元，并均于当月转回，累计涉及金额为2.2 ...